View Featured Offers >>

MEDx and CST Expand Partnership for Companion Diagnostic (CDx) Development for the Chinese Market

Danvers, MA, USA, and Shanghai, China, October 10, 2023

Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, and MEDx Translational Medicine (MEDx), a company dedicated to developing companion diagnostics and total-solution provider in precision medicine, today announced the expansion of their ongoing partnership for companion diagnostic (CDx) development to meet growing demand in China. As part of the agreement, CST will provide MEDx with expanded access to antibodies for crucial CDx targets to address key clinical needs in China.

"We are proud to work closely with our international partners to enable the translation of research and pre-clinical applications into CDx assays, and are excited to continue our partnership with MEDx to support their commitment to advancing precision medicine in China,” said Roberto Polakiewicz, Chief Scientific Officer at CST. “By combining our expertise in developing highly specific, sensitive antibodies with MEDx’s experience in companion diagnostics development and clinical services, we are enabling advanced, targeted, immune, and other cell therapies that promise new cures to devastating diseases.”

SignalStar Multiplex IHC

Immunohistochemical analysis of paraffin-embedded human lung carcinoma using PD-L1 (E1L3N®) XP® Rabbit mAb #13684.

The announcement follows the successful development and approval by the National Medical Products Administration of a MEDx CDx assay kit for PD-L1 using the CST® antibody. In the next phase of the partnership, the companies will establish feasibility testing to facilitate the expansion of companion diagnostics for specific indications, with a focus on relevant oncology targets. Using CST’s highly validated portfolio of best-in-class antibody* products, MEDx will develop clinical tests for the diagnosis of disease, monitoring and assessing treatment efficacy, or identification of patients predicted to respond to innovative targeted therapies.

The continued expansion of precision medicine in China presents remarkable prospects for the pharmaceutical and healthcare sectors,” said Nick Zhang, CEO of MEDx. “MEDx can provide total-solution translational medicine technology enabling clinical transformation of drugs, CDx development, and clinical testing for precision medicine. This partnership further strengthens our relationship with CST and harnesses our comprehensive solutions to create new companion diagnostic products that will meet the needs of China’s growing market in precision medicine.”

*In 2022, the most recent year for which data is available, CST was named the top antibody Supplier Succeeding in Cancer Research by CiteAb, and over one-third of the products in CiteAb’s Top 100 Cited Antibodies of 2022 were CST products, more than any other antibody supplier.

About Cell Signaling Technology

Cell Signaling Technology (CST) is a different kind of life science company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. Founded in 1999 and headquartered in Danvers, Massachusetts, USA, CST employs over 600 people worldwide. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery. CST is a company of caring people driven by a devotion to facilitating good science—a company committed to doing the right thing for our Customers, our communities, and our planet.

About MEDx

MEDx Translational Medicine Co., Ltd (MEDx) was founded in 2013 and rooted from Qiagen (Suzhou) Translational Medicine, Co., Ltd in China. As a leader of Companion Diagnostics Total-Solution Providers, MEDx is committed to offering comprehensive translational medicine support in the development of new drugs and companion diagnostics (CDx) in oncology as well as providing clinical testing for precision medicine. MEDx has already cooperated with 400 innovative pharmaceutical and biotechnological companies. There are more than 20 diagnostic products approved and available for the global market, and among them are PD-L1 companion diagnostic kit and JAK2 V617F mutation testing for MPN. Products are used to predict cancer treatment responses in both solid tumors and hematological malignancies. We believe MEDx is your ideal partner to meet your needs and help guide personalized treatment of patients.

CST Media and Press

Rebecca J. Reppucci, MBA
Cell Signaling Technology, Inc.
Senior Director, Global MarComm & Technology
Phone: 978-880-3334
email: [email protected]

MEDx Translational Medicine Co. Ltd.

Dr. James Tang, VP of Marketing
email: [email protected]